A minority subpopulation of CD133+/EGFRvIII+/EGFR- cells acquires stemness and contributes to gefitinib resistance

21Citations
Citations of this article
29Readers
Mendeley users who have this article in their library.

Abstract

Aims: To study the contribution of epidermal growth factor receptor variant III (EGFRvIII) to glioblastoma multiforme (GBM) stemness and gefitinib resistance. Methods: CD133+ and CD133- cells were separated from EGFRvIII+ clinical specimens of three patients with newly diagnosed GBM. Then, RT-PCR was performed to evaluate EGFRvIII and EGFR expression in CD133+ and CD133- cells. The tumorigenicity and stemness of CD133+ cells was verified by intracranial implantation of 5 × 103 cells into immunodeficient NOD/SCID mice. Finally, cells were evaluated for their sensitivity to EGFR tyrosine kinase inhibition by gefitinib. Results: RT-PCR results showed that the sorted CD133+ cells expressed EGFRvIII exclusively, while the CD133- cells expressed both EGFRvIII and EGFR. At 6-8 weeks postimplantation, CD133+/EGFRvIII+/EGFR- cells formed intracranial tumors. Cell counting kit-8 results showed that the IC50 values of the three isolated EGFRvIII+ cell lines treated with gefitinib were 14.44, 16.00, and 14.66 μM, respectively, whereas the IC50 value of an isolated EGFRvIII- cell line was 8.57 μM. Conclusions: EGFRvIII contributes to the stemness of cancer stem cells through coexpression with CD133 in GBMs. Furthermore, CD133+/EGFRvIII+/EGFR- cells have the ability to initiate tumor formation and may contribute to gefitinib resistance. © 2013 John Wiley & Sons Ltd.

Cite

CITATION STYLE

APA

Liu, X. J., Wu, W. T., Wu, W. H., Yin, F., Ma, S. H., Qin, J. Z., … Shen, L. (2013). A minority subpopulation of CD133+/EGFRvIII+/EGFR- cells acquires stemness and contributes to gefitinib resistance. CNS Neuroscience and Therapeutics, 19(7), 494–502. https://doi.org/10.1111/cns.12092

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free